AHR and breast carcinoma: Following ligand binding in breast cancer cells, AhR can activate two pathways, an X/DRE-mediated DNA binding pathway and/or a non-X/DRE-mediated protein-protein interaction pathway, both of which can lead to changes in gene expression.